Correlation of intraluminal thrombosis in brain tumor vessels with postoperative thrombotic complications: a preliminary report.
OBJECTIVE
Thrombotic complications (deep vein thrombosis and/or pulmonary embolization [DVT/PE]) occur in 18 to 50% of patients harboring brain tumors who undergo neurosurgical procedures. Such patients are at risk for DVT/PE because of immobility, paresis, hypovolemia, and lengthy surgery. The present study was undertaken to see whether tumor patients at highest risk for DVT/PE could be identified so that augmentation of prophylactic measures might be used to reduce the incidence of thrombotic complications.


METHODS
The authors conducted a retrospective analysis of 488 patients enrolled in their brain tumor registries between 1988 and 1995, identifying 57 patients (12%) with recorded symptomatic DVT, PE, or both postoperatively. In 24 of these 57 cases histological specimens were retrievable for review, allowing an in-depth analysis. Forty-five patients were lost to follow-up review, and the remaining 386 patients had no record of systemic thrombosis. Slides of pathological specimens were retrievable in 50 cases in which there was no DVT/PE. From these 50 cases, 25 were selected at random to represent the control group by a blinded observer. Seventeen (71%) of the 24 brain tumor specimens obtained in patients with DVT/PE stained positively for intraluminal thrombosis (ILT) after hematoxylin and eosin had been applied. The odds ratio associated with the presence of ILT was 17.8, with a confidence interval ranging from 4 to 79.3. No evidence of ILT was found in 22 patients (88%) within the control group (p < 0.0001, Fisher's exact test). Other factors that may predispose patients with brain tumors to DVT/PE-limb paresis, extent of tumor removal, and duration of the surgery-were also analyzed and found not to be statistically significant. Therefore, these factors were not the basis for differences seen between the study and control groups.


CONCLUSIONS
These preliminary observations suggest that the presence of ILT within malignant glioma or glioblastoma tumor vessels may represent a marker of tumor-induced hypercoagulability.
Rodas
R A
RA
Department of Neurosurgery, Roswell Park Cancer Institute, Buffalo, New York 14263, USA.
Fenstermaker
R A
RA
McKeever
P E
PE
Blaivas
M
M
Dickinson
L D
LD
Papadopoulos
S M
SM
Hoff
J T
JT
Hopkins
L N
LN
Duffy-Fronckowiak
M
M
Greenberg
H S
HS
D000328:Adult; D000368:Aged; D014408:Biomarkers, Tumor; D001810:Blood Volume; D001932:Brain Neoplasms / Q000098:blood supply* / Q000601:surgery; D004396:Coloring Agents; D016001:Confidence Intervals; D005260:Female; D005456:Fluorescent Dyes; D005500:Follow-Up Studies; D005909:Glioblastoma / Q000098:blood supply / Q000601:surgery; D005910:Glioma / Q000098:blood supply / Q000601:surgery; D006801:Humans; D007103:Immobilization; D015994:Incidence; D008297:Male; D008875:Middle Aged; D016017:Odds Ratio; D010291:Paresis / Q000150:complications; D011183:Postoperative Complications / Q000517:prevention & control; D011655:Pulmonary Embolism / Q000209:etiology* / Q000517:prevention & control; D012042:Registries; D012189:Retrospective Studies; D012307:Risk Factors; D016037:Single-Blind Method; D013924:Thrombophlebitis / Q000209:etiology* / Q000517:prevention & control; D013927:Thrombosis / Q000150:complications*; D013997:Time Factors
D014408:Biomarkers, Tumor; D004396:Coloring Agents; D005456:Fluorescent Dyes